AGE-DEFYING EYE SERUMClinical Efficacy Overview

ABSTRACT To address the appearance of fine lines, crow’s feet, dark circles and under eye puffiness, Nerium created the innovative Age-Defying Eye Serum. In an 8-week third-party clinical study among females between the ages of 45-70 years of age, the Age-Defying Eye Serum showed improvements on all clinical efficacy grading parameters at all time points evaluated (immediate, 4 and 8 weeks of use) with twice a day application of the Eye Serum. Notable improvements in the key targets for the Eye Serum — fine lines (crow’s feet area), dark circles (under the eye area) and puffiness (crow’s feet area) — were observed at the 8-week time point.

DEMOGRAPHICS • 102 females• At least 20 subjects of each ethnicity:

• Caucasian• African-American• Asian• Hispanic

• All were between the ages of 45-70 years of age.

METHOD • 8-week monadic study with four visits to the test facility —

baseline, 2, 4 and 8 weeks.• Clinical grading, imaging and bioinstrumentation measures

were conducted at baseline, 2, 4 and 8 weeks.• The Visia CR imaging system and the SWIRL method (Stephens

Wrinkle Imaging using Raking Light) were used to assess the number, length, width and depth of wrinkles in the crow’s feet area.

• Subjects completed a self-assessment questionnaire at week 8.

CLINICAL EFFICACY EXPERT GRADINGKEY IMMEDIATE BENEFITS*

Parameter % Panelist Improvement

Fine lines (under eye area) 67

Fine lines (crow’s feet area) 60

Clarity/Brightness (eye area) 51

*Results compared to baseline; testing hypothesis is that the mean change from baseline is equal to zero. Calculated from Wilcoxon signed-rank test. Differences are based on a 95% confidence level.

CLINICAL EFFICACY EXPERT GRADING KEY LONG-TERM BENEFITS*

Time Point (Wk) Parameter % Panelist

Improvement

8 Fine lines (crow’s feet area) 89

8 Clarity/Brightness (eye area) 80

8 Overall appearance (eye area) 68

8 Dark circles (under eye area) 67

8 Firmness (eye area) 66

*Results compared to baseline; testing hypothesis is that the mean change from baseline is equal to zero. Calculated from Wilcoxon signed-rank test. Differences are based on a 95% confidence level.

KEY BENEFITS Based on a clinically-graded evaluation:• Participants showed an immediate reduction in the appearance

of crow’s feet, puffiness and dark circles and showed continued improvement with 4 weeks of use.

• 67% of the participants showed an improvement in the appearance of dark circles after 8 weeks of use.

• 89% of the participants showed a decrease in the appearance of fine lines around the crow’s feet area after 8 weeks of use.

• 80% of the participants showed brighter skin in the eye area after 8 weeks of use.

• Participants showed improvement in firmness in the eye area immediately and with continued use.

• Participants showed an immediate improvement in the appearance of puffiness around the eye.

2 WEEK BEFORE/AFTER IMAGES

Baseline 2 Weeks

8 WEEK BEFORE/AFTER IMAGES

Baseline 8 Weeks

4 WEEK BEFORE/AFTER IMAGES

Baseline 4 Weeks

8 WEEK BEFORE/AFTER IMAGES

Baseline 8 Weeks